Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Singh Cheema, Philip A. Dy, Timothy E. O'Brien, Jane N. Winter, Terrence P. Cescon, Julie E. Chang, Brad S. Kahl

Clin Cancer Res (2020) 26 (17): 4468–4477.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-1345

Published: 01 September 2020

View article

Includes: Supplementary data

Journal Articles

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clin Cancer Res (2017) 23 (15): 4127–4137.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2818

Published: 01 August 2017

View article

Includes: Supplementary data

Journal Articles

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8⁺ T Cells

Julie S. Nielsen, Colin G. Sedgwick, Aniqa Shahid, Zusheng Zong, Zabrina L. Brumme, Stephen Yu, Lewis Liu, David R. Kroeger, Steven P. Treon, Joseph M. Connors, Randy D. Gascoyne, Brian R. Berry, Marco A. Marra, Ryan D. Morin, Nicol Macpherson, Brad H. Nelson

Clin Cancer Res (2016) 22 (9): 2226–2236.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2023

Published: 01 May 2016

View article

Includes: Supplementary data

Journal Articles

Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma

Vaishalee P. Kenkre, Fangxin Hong, James R. Cerhan, Marcia Lewis, Leslie Sullivan, Michael E. Williams, Randy D. Gascoyne, Sandra J. Horning, Brad S. Kahl

Clin Cancer Res (2016) 22 (4): 821–826.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1848

Published: 14 February 2016

View article

Journal Articles

Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment

Andrew J. Gentles, Ash A. Alizadeh, Alvaro J. Alencar, Holbrook E. Kohrt, Roch Houot, Matthew J. Goldstein, Yasodha Natkunam, Ranjana H. Advani, Randy D. Gascoyne, Javier Briones, Sylvia K. Plevritis, Izidore S. Lossos, Ronald Levy

Clin Cancer Res (2010) 16 (14_Supplement): PR5.

DOI: https://doi.org/10.1158/1078-0432.TCMUSA10-PR5

Published: 02 February 2016

View article

Journal Articles

Abstract A19: MALT1 inhibition as an anchor for combinatorial therapy of ABC-DLBCL.

Lorena Fontan, Chenghua Yang, Himaly Shinglot, Venkataraman Kabaleeswaran, Volpon Laurent, Michael Osborne, Elena Beltran, Monica Rosen, Rita Shaknovich, Shao N. Yang, Randy D. Gascoyne, Leandro Cerchietti, Jose A. MArtinez-Climent, J Fraser Glickman, KAtherine Borden, Hao Wu, Ari Melnick

Clin Cancer Res (2015) 21 (17_Supplement): A19.

DOI: https://doi.org/10.1158/1557-3265.HEMMAL14-A19

Published: 19 August 2015

View article

Journal Articles

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

Clin Cancer Res (2015) 21 (15): 3428–3435.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-3253

Published: 02 August 2015

View article

Includes: Supplementary data

Journal Articles

Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake

Anja Mottok, Randy D. Gascoyne

Clin Cancer Res (2015) 21 (1): 4–6.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1651

Published: 05 January 2015

View article

Journal Articles

BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

Clin Cancer Res (2011) 17 (24): 7785–7795.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-0267

Published: 18 December 2011

View article

Includes: Supplementary data

Journal Articles

MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

Alvaro J. Alencar, Raquel Malumbres, Goldi A. Kozloski, Ranjana Advani, Neha Talreja, Shideh Chinichian, Javier Briones, Yasodha Natkunam, Laurie H. Sehn, Randy D. Gascoyne, Rob Tibshirani, Izidore S. Lossos

Clin Cancer Res (2011) 17 (12): 4125–4135.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-0224

Published: 15 June 2011

View article

Includes: Supplementary data

Journal Articles

Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues

Lisa M. Rimsza, George Wright, Mark Schwartz, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Andreas Rosenwald, German Ott, James R. Cook, Raymond R. Tubbs, Rita M. Braziel, Jan Delabie, Tom P. Miller, Louis M. Staudt

Clin Cancer Res (2011) 17 (11): 3727–3732.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2573

Published: 01 June 2011

View article

Journal Articles

Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

Clin Cancer Res (2010) 16 (8): 2435–2442.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-1219

Published: 14 April 2010

View article

Includes: Supplementary data

Journal Articles

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

Clin Cancer Res (2009) 15 (17): 5494–5502.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-0113

Published: 31 August 2009

View article

Includes: Supplementary data

Journal Articles

Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma

Alison H. Banham, Joseph M. Connors, Philip J. Brown, Jacqueline L. Cordell, German Ott, Gayatri Sreenivasan, Pedro Farinha, Douglas E. Horsman, Randy D. Gascoyne

Clin Cancer Res (2005) 11 (3): 1065–1072.

DOI: https://doi.org/10.1158/1078-0432.1065.11.3

Published: 11 February 2005

View article

Journal Articles

Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide

Richard J. Klasa, Marcel B. Bally, Rebecca Ng, James H. Goldie, Randy D. Gascoyne, Frances M. P. Wong

Clin Cancer Res (2000) 6 (6): 2492–2500.

Published: 01 June 2000

View article

NARROW

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8⁺ T Cells

Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma

Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment

Abstract A19: MALT1 inhibition as an anchor for combinatorial therapy of ABC-DLBCL.

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake

BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues

Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma

Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only